Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Fast Track Designation to 67Cu-SAR-bisPSMA, a targeted ... Read More
Clarity Pharmaceuticals advances in SECuRE trial with promising prostate cancer treatment results
Clarity Pharmaceuticals (ASX: CU6), a clinical stage radiopharmaceutical company, announced significant progress in the SECuRE trial, marking a pivotal step in cancer treatment research. The ... Read More